Clinical trial
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic…
NCT00473005 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00473005 |
|---|---|
| Title | Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast |
| Official title | A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, RAD001 |
| Enrollment | 18 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | May 14, 2007 |
| Last update posted | May 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: